Sign in
Taking people in New ZealandPhase 1

OM336 for Sjogren's disease or inflammatory muscle disease

Tests the safety of OM336 injections in adults with Sjogren's disease or myopathy.

Key facts

Who runs it
Lakefront Biotherapeutics West LLC
Where
Hamilton, New ZealandSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
OM336 in Seropositive Autoimmune Diseases
Status
Recruiting
Phase
Phase 1
People taking part
39 people, planned
Started
1 Oct 2025
Expected to end
Mar 2028
Type of study
Interventional
Treatments tested
  • OM336
Record updated
15 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active Sjogren's disease or idiopathic inflammatory myopathy (a muscle inflammation disease) with autoantibodies in the blood. The disease must have come back or not responded after earlier treatments.

Age
18 Years to 75 Years
Sex
All sexes can join.
Disease stage
Active seropositive autoimmune disease (Sjogren's disease or idiopathic inflammatory myopathy) that has come back or not responded to treatment.
Earlier treatment
At least 2 prior or ongoing treatments. People who had a BCMA-targeted therapy before cannot join.
Biomarker or test result
Seropositive disease: autoantibodies found in a blood test.

Main reasons for not taking part

  • Earlier treatment with a BCMA-targeted therapy
  • Serious infection within 3 months of screening
  • Major surgery within 3 months of screening or planned during the study
  • Pregnant or breastfeeding
  • Body weight under 50 kg (110 lb)

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Diagnosis of active seropositive autoimmune disease
  • Relapsed/refractory after ≥2 prior/ongoing treatments
  • Body weight ≥ 50 kg
  • Willing to comply with and study requirements and procedures

Who cannot take part

  • Previous treatment with a BCMA-targeted therapy
  • Major surgery within 3 months of screening or planned during the study
  • Clinically significant infection within 3 months of screening
  • Pregnant or breastfeeding

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in New Zealand.

Also in 1 other country, 1 site

  • Waikato HospitalHamilton, New ZealandContact: Study SponsorTaking people

About the trial

What the trial wants to find out

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.

The group in the trial

  • OM336 Dose EscalationTreatment being tested

    Participants will receive OM336 via subcutaneous injection in ascending dose cohorts

    Treatment: OM336

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy
Plain-language title
OM336 for Sjogren's disease or inflammatory muscle diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07229144, who can take part
Record updated
15 June 2026